Clinical Trial

Extracellular Vesicles for HD

Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to discover blood-based biomarker of brain Huntingtin (HTT) protein using extracellular vesicles to be used in evaluating target engagement in HTT lowering clinical trials. Secondary objectives of this study include developing more accurate biomarkers of Huntington disease (HD) progression or conversion and to develop standard practices for extracellular vesicle biomarker discovery research. The investigators hypothesize that brain-derived extracellular vesicles (EVs) isolated from human biofluids contain biological cargo specific to their tissue of origin that could allow their use as brain biomarkers for HD. EVs are lipid bilayer-delimited particles that are naturally released from cells in the brain. The investigators will investigate if EVs contents reflect the pathological alterations occurring with disease progression when compared with EVs isolated from biofluids of healthy non-HD persons.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-08; most recent amendment 2024-12-03.
Status change: Not Yet Recruiting → Recruiting 2023-11-04
Trial Details
NCT Number NCT06082713
Lead Sponsor University of Central Florida
Collaborators: University of South Florida
Conditions Huntington Disease
Enrollment 100 participants
Start Date 2023-10-25
Primary Completion 2031-11 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2024-12-06